Intra-Cellular Therapies Sees Unusually High Options Volume (ITCI)

Intra-Cellular Therapies Inc (NASDAQ:ITCI) was the recipient of unusually large options trading activity on Wednesday. Investors purchased 1,000 put options on the company. This represents an increase of approximately 1,438% compared to the average volume of 65 put options.

In other Intra-Cellular Therapies news, SVP Michael Halstead sold 25,500 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $18.03, for a total transaction of $459,765.00. Following the transaction, the senior vice president now owns 191 shares in the company, valued at approximately $3,443.73. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Lawrence J. Hineline sold 49,700 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $20.02, for a total transaction of $994,994.00. The disclosure for this sale can be found here. Corporate insiders own 19.80% of the company’s stock.

How to Become a New Pot Stock Millionaire

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth approximately $101,000. SG Americas Securities LLC lifted its holdings in shares of Intra-Cellular Therapies by 45.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock worth $190,000 after acquiring an additional 3,794 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $212,000. UBS Asset Management Americas Inc. bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $213,000. Finally, First Mercantile Trust Co. lifted its stake in Intra-Cellular Therapies by 77.3% in the 4th quarter. First Mercantile Trust Co. now owns 15,588 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 6,797 shares during the last quarter. 70.47% of the stock is owned by institutional investors.



Shares of Intra-Cellular Therapies stock opened at $19.90 on Thursday. Intra-Cellular Therapies has a 1-year low of $7.85 and a 1-year high of $25.82. The company has a market cap of $1,114.39, a PE ratio of -9.39 and a beta of 0.59.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). Intra-Cellular Therapies had a negative return on equity of 26.67% and a negative net margin of 39,745.53%. The firm had revenue of $5.06 million for the quarter, compared to the consensus estimate of $0.05 million. During the same period last year, the company posted ($0.64) EPS. The business’s revenue was down 94.8% on a year-over-year basis. research analysts forecast that Intra-Cellular Therapies will post -3.33 earnings per share for the current year.

ITCI has been the topic of a number of analyst reports. BidaskClub upgraded shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. ValuEngine lowered shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada initiated coverage on shares of Intra-Cellular Therapies in a research report on Thursday, February 8th. They set an “outperform” rating and a $33.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.27.

COPYRIGHT VIOLATION WARNING: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://stocknewstimes.com/2018/04/19/intra-cellular-therapies-sees-unusually-high-options-volume-itci.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply